Tyrosine kinase receptor B protects against coronary artery disease and promotes adult vasculature integrity by regulating Ets1-Mediated VE-Cadherin expression

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 3, 2015, Pages 580-588

  Jiang, Hong ^a   Huang, Shuhong ^b   Li, Xinyun ^b   Li, Xian ^a   Zhang, Yun ^a   Chen, Zhe Yu ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Brain derived neurotrophic factor; Cadherin 5; Coronary artery disease

Indexed keywords

APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS1; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; CADHERIN; ETS1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; NTRK2 PROTEIN, MOUSE; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR ETS 1; TROPOMYOSIN-RELATED KINASE-B, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTIC ENDOTHELIAL CELL; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; GENE SILENCING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEART PROTECTION; HOMOZYGOTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VASCULAR ENDOTHELIAL CELL; ANIMAL; ASIAN CONTINENTAL ANCESTRY GROUP; ATHEROSCLEROSIS; CAPILLARY PERMEABILITY; CHINA; CORONARY BLOOD VESSEL; CORONARY STENOSIS; DEFICIENCY; DISEASE MODEL; ENDOTHELIUM CELL; ENZYMOLOGY; ETHNOLOGY; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; HELA CELL LINE; HETEROZYGOTE; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHENOTYPE; PROTECTION; RISK FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR;

ANIMALS; ANTIGENS, CD; APOLIPOPROTEINS E; ASIAN CONTINENTAL ANCESTRY GROUP; ATHEROSCLEROSIS; CADHERINS; CAPILLARY PERMEABILITY; CASE-CONTROL STUDIES; CHINA; CORONARY STENOSIS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENETIC PREDISPOSITION TO DISEASE; HELA CELLS; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MEMBRANE GLYCOPROTEINS; MICE, KNOCKOUT; PHENOTYPE; POLYMORPHISM, GENETIC; PROTECTIVE FACTORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEIN C-ETS-1; RISK FACTORS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84922251345     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304405     Document Type: Article

References (28)

1. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007;7:803-815. doi: 10.1038/nri2171.
2. Skålén K, Gustafsson M, Rydberg EK, Hultén LM, Wiklund O, Innerarity TL, Borén J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417:750-754. doi: 10.1038/nature00804.
3. Choy JC, Granville DJ, Hunt DW, McManus BM. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol. 2001;33:1673-1690. doi: 10.1006/ jmcc.2001.1419.
4. Okada S, Yokoyama M, Toko H, Tateno K, Moriya J, Shimizu I, Nojima A, Ito T, Yoshida Y, Kobayashi Y, Katagiri H, Minamino T, Komuro I. Brain-derived neurotrophic factor protects against cardiac dysfunction after myocardial infarction via a central nervous system-mediated pathway. Arterioscler Thromb Vasc Biol. 2012;32:1902-1909. doi: 10.1161/ ATVBAHA.112.248930.
5. Wagner N, Wagner KD, Theres H, Englert C, Schedl A, Scholz H. Coronary vessel development requires activation of the TrkB neurotrophin receptor by the Wilms' tumor transcription factor Wt1. Genes Dev. 2005;19:2631-2642. doi: 10.1101/gad.346405.
6. Donovan MJ, Lin MI, Wiegn P, Ringstedt T, Kraemer R, Hahn R, Wang S, Ibañez CF, Rafii S, Hempstead BL. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development. 2000;127:4531-4540.
7. Ribases M, Gratacos M, Badia A, Jimenez L, Solano R, Vallejo J, Fernandez-Aranda F, Estivill X. Contribution of NTRK2 to the genetic susceptibility to anorexia nervosa, harm avoidance and minimum body mass index. Mol Psychiatry. 2005;10:851-860. doi: 10.1038/sj.mp.4001670.
8. Hoogendoorn B, Coleman SL, Guy CA, Smith K, Bowen T, Buckland PR, O'Donovan MC. Functional analysis of human promoter polymorphisms. Hum Mol Genet. 2003;12:2249-2254. doi: 10.1093/hmg/ddg246.
9. Kraemer R, Baker PJ, Kent KC, Ye Y, Han JJ, Tejada R, Silane M, Upmacis R, Deeb R, Chen Y, Levine DM, Hempstead B. Decreased neurotrophin TrkB receptor expression reduces lesion size in the apolipoprotein E-null mutant mouse. Circulation. 2005;112:3644-3653. doi: 10.1161/ CIRCULATIONAHA.105.587980.
10. Gotsch U, Borges E, Bosse R, Böggemeyer E, Simon M, Mossmann H, Vestweber D. VE-cadherin antibody accelerates neutrophil recruitment in vivo. J Cell Sci. 1997;110(Pt 5):583-588.
11. Lelièvre E, Mattot V, Huber P, Vandenbunder B, Soncin F. ETS1 lowers capillary endothelial cell density at confluence and induces the expression of VE-cadherin. Oncogene. 2000;19:2438-2446. doi: 10.1038/ sj.onc.1203563.
12. Heo SH, Choi YJ, Ryoo HM, Cho JY. Expression profiling of ETS and MMP factors in VEGF-activated endothelial cells: role of MMP-10 in VEGF-induced angiogenesis. J Cell Physiol. 2010;224:734-742. doi: 10.1002/jcp.22175.
13. Rossi GP, Cesari M, Zanchetta M, Colonna S, Maiolino G, Pedon L, Cavallin M, Maiolino P, Pessina AC. The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol. 2003;41:930-937.
14. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med. 2000;6:460-463. doi: 10.1038/74725.
15. Ahmed A, Fujisawa T, Niu XL, Ahmad S, Al-Ani B, Chudasama K, Abbas A, Potluri R, Bhandari V, Findley CM, Lam GK, Huang J, Hewett PW, Cudmore M, Kontos CD. Angiopoietin-2 confers Atheroprotection in apoE-/- mice by inhibiting LDL oxidation via nitric oxide. Circ Res. 2009;104:1333-1336. doi: 10.1161/CIRCRESAHA.109.196154.
16. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, Virchow JC. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging. 2005;26:115-123. doi: 10.1016/j.neurobiolaging.2004.03.002.
17. Manni L, Nikolova V, Vyagova D, Chaldakov GN, Aloe L. Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. Int J Cardiol. 2005;102:169-171. doi: 10.1016/j.ijcard.2004.10.041.
18. Prigent-Tessier A, Quirié A, Maguin-Gaté K, Szostak J, Mossiat C, Nappey M, Devaux S, Marie C, Demougeot C. Physical training and hypertension have opposite effects on endothelial brain-derived neurotrophic factor expression. Cardiovasc Res. 2013;100:374-382. doi: 10.1093/cvr/cvt219.
19. Personius KE, Parker SD. TrkB expression at the neuromuscular junction is reduced during aging. Muscle Nerve. 2013;47:532-538. doi: 10.1002/ mus.23616.
20. Webster MJ, Herman MM, Kleinman JE, Shannon Weickert C. BDNF and trkB mRNA expression in the hippocampus and temporal cortex during the human lifespan. Gene Expr Patterns. 2006;6:941-951. doi: 10.1016/j. modgep.2006.03.009.
21. Herren B, Levkau B, Raines EW, Ross R. Cleavage of beta-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. Mol Biol Cell. 1998;9:1589-1601.
22. Miyazaki T, Taketomi Y, Takimoto M, Lei XF, Arita S, Kim-Kaneyama JR, Arata S, Ohata H, Ota H, Murakami M, Miyazaki A. m-Calpain induction in vascular endothelial cells on human and mouse atheromas and its roles in VE-cadherin disorganization and atherosclerosis. Circulation. 2011;124:2522-2532. doi: 10.1161/CIRCULATIONAHA.111.021675.
23. Gulino D, Delachanal E, Concord E, Genoux Y, Morand B, Valiron MO, Sulpice E, Scaife R, Alemany M, Vernet T. Alteration of endothelial cell monolayer integrity triggers resynthesis of vascular endothelium cadherin. J Biol Chem. 1998;273:29786-29793.
24. Bostick B, Ghosh A, Yue Y, Long C, Duan D. Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther. 2007;14:1605-1609. doi: 10.1038/sj.gt.3303029.
25. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther. 2012;20:699-708. doi: 10.1038/mt.2011.287.
26. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12:341-355. doi: 10.1038/nrg2988.
27. High KA, Aubourg P. rAAV human trial experience. Methods Mol Biol. 2011;807:429-457. doi: 10.1007/978-1-61779-370-7-18.
28. Kaeppel C, Beattie SG, Fronza R, van Logtenstein R, Salmon F, Schmidt S, Wolf S, Nowrouzi A, Glimm H, von Kalle C, Petry H, Gaudet D, Schmidt M. A largely random AAV integration profile after LPLD gene therapy. Nat Med. 2013;19:889-891. doi: 10.1038/nm.3230.